Chemotype Evolution (CE) is a discovery platform designed to efficiently identify and optimize drug candidates by completing successive iterations of library synthesis and screening.
CE enabled the exploration of chemical diversity in a target-specific manner, and eventually led to the identification of novel incretin targeted product candidates that comprise our pipeline. Our three clinical-stage product candidates are being evaluated for safety and efficacy in people with obesity, type 2 diabetes and type 1 diabetes.
Once we have identified a target of interest, our CE platform is designed to efficiently optimize drug candidates by completing successive iterations of library synthesis and screening. With each round of testing, we gain insights into target function and potential new product candidate leads. By iteratively tuning the pharmacology of our product candidates, we aim to identify the optimal development candidate to progress. The platform enabled the generation of a pipeline of programs designed to have potent and selective signaling properties as well as other favorable attributes including bioavailability, the proportion of the drug that has an active effect, and half-life. We believe a key differentiator of our product candidates is that they were purposefully designed with biased-signaling, which could improve the therapeutic window of our product candidates.